Combined Use of Raltitrexed and S-1 as Treatment for Patients With Metastasizing Colorectal Cancer
The primary endpoint is to evaluate the Median disease progression free survival (mPFS).
Metastatic Colon Cancer
DRUG: Raltitrexed and S-1
Median disease progression free survival (mPFS) of Raltitrexed combined with S-1, at least 24 months
The primary endpoint is to evaluate the disease progression free survival (mPFS) of Raltitrexed combined with S-1 as treatment for patients with metastasizing colorectal cancer failed of standard chemotherapy